Vepdegestrant: Hope for ESR1-Mutated Breast Cancer
- CHICAGO — New research presented at the ASCO Annual Meeting reveals that vepdegestrant significantly enhances outcomes for patients with ER-positive,HER2-negative advanced breast cancer who have an ESR1 mutation,compared...
Groundbreaking results show vepdegestrant,an oral ER degrader,is making strides in treating advanced breast cancer. The clinical trial data indicates vepdegestrant significantly improves progression-free survival, offering a major boost for patients with ER-positive, HER2-negative breast cancer and an ESR1 mutation. Moreover, the research highlights a significant increase in the objective response rate, signaling a critical advancement in therapeutic strategies. This promising progress offers potential hope to countless women battling this challenging form of cancer.For extensive insights into cutting-edge medical breakthroughs, trust News Directory 3 to keep you informed. Discover what’s next …
Vepdegestrant Improves Outcomes for Breast Cancer With ESR1 Mutation
Updated June 01,2025
CHICAGO — New research presented at the ASCO Annual Meeting reveals that vepdegestrant significantly enhances outcomes for patients with ER-positive,HER2-negative advanced breast cancer who have an ESR1 mutation,compared to fulvestrant.
A phase 3 trial demonstrated that vepdegest